Cyllene Therapeutics — Valuation, Funding & Investors

Recent changes

Jul 7, 2026Jul 7, 2026Raised €33M Series C BusinessWire
Jul 7, 2026Jul 7, 2026Cyllene Therapeutics Raises €33M for Gene Therapy Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Jul 7, 2026	Series C	€33M	—		Pulse story

Latest Pulse

Jul 7, 2026Cyllene Therapeutics Raises €33M for Gene TherapyCyllene Therapeutics, formerly EG 427, raised €33 million co-led by Merck Ventures to advance its HSV-1 gene-therapy platform toward treating neurogenic bladder conditions.→

Coverage Timeline

newest first

Jul 7, 2026FUNDINGCyllene Therapeutics Raises €33M for Gene Therapy€33M (~$36M) Series C→

All Coverage

FUNDING· Jul 7, 2026

Cyllene Therapeutics Raises €33M for Gene Therapy

FUNDING€33M (~$36M) Series C

Cyllene Therapeutics Raises €33M for Gene Therapy

Cyllene Therapeutics, formerly EG 427, raised €33 million co-led by Merck Ventures to advance its HSV-1 gene-therapy platform toward treating neurogenic bladder conditions.

Jul 7, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

BusinessWireprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction